This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00926/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00926/identifier/wikipedia/
n18http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00926/identifier/pubchem-compound/
n16http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00926/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00926/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00926/identifier/drugbank/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00926/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00926/identifier/chebi/

Statements

Subject Item
n2:DB00926
rdf:type
n5:Drug
n5:description
Etretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid. The mechanism of action of etretinate is still incompletely understood although, like retinoic acid, it is thought to interfere with the terminal differentiation of keratinocytes. It is thought to bind to the retinoic acid receptors. Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases. It was removed from the United States market in 1998 and the Canadian market in 1996 as a psoriasis medication, due to the high risk of birth defects. Etretinate is now used to treat T-cell lymphomas. It also appears to inhibit NADH oxidase activity.
n5:group
withdrawn
n5:halfLife
In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.
n5:indication
For the treatment of severe psoriasis in adults.
n5:manufacturer
n18:271B6216-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00926 n16:DB00926
dcterms:title
Etretinate
adms:identifier
n4:Etretinate n7:3196 n8:DB00926 n9:4913 n12:5282375 n13:46504486 n14:D00316 n15:PA449554
n5:mechanismOfAction
The mechanism of action of the active metabolite, acitretin, is unknown, however it is believed to work by targeting specific receptors (retinoid receptors) in the skin which help normalize the growth cycle of skin cells.
n5:toxicity
Symptoms of overdose include headache and vertigo.
n5:foodInteraction
Avoid alcohol completely up to 2 months after discontinuation. Increases absorption, take with food.
n5:proteinBinding
More than 99% bound to plasma proteins, predominantly lipoproteins, whereas its active metabolite, acetretin (etretin), is predominantly bound to albumin.
n5:synthesisReference
Bollag. W., Ruegg, R. and Ryser, G.; U.S.Patent 4,105,681; August 8,1978; assigned to Hoffmann-LaRoche, Inc. Bollag, W., Ruegg, R. and Ryser, G.; U.S. Patent 4,215,215; July 29, 1980; assigned to Hoffmann-La Roche, Inc.
n5:IUPAC-Name
n6:271B621B-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B6221-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B6220-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B621D-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B621E-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B621F-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B6219-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B6217-363D-11E5-9242-09173F13E4C5 n6:271B621A-363D-11E5-9242-09173F13E4C5 n6:271B6231-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B6218-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B6227-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B6228-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B6222-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B6223-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B6225-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B6224-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B6226-363D-11E5-9242-09173F13E4C5
n5:absorption
Absorbed in the small intestine. Studies in normal volunteers indicate that the absorption of etretinate is greater in patients consuming whole milk or a high-fat diet than in patients in a fasting state.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
54350-48-0
n5:Bioavailability
n6:271B622C-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B622E-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B622F-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B6230-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B622B-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B622A-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B622D-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B621C-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B6229-363D-11E5-9242-09173F13E4C5